...
首页> 外文期刊>Cancer chemotherapy and pharmacology. >The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma
【24h】

The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma

机译:泼尼松,依托泊苷和环磷酰胺的节律疗法可降低复发或难治性非霍奇金淋巴瘤患者的血清VEGF和循环内皮细胞水平,并提高应答率和无进展生存率

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose There is an urgent need for a better strategy in the management of relapsed or refractory non-Hodgkin's lymphoma (NHL). The present study was designed to evaluate the efficacy and safety of the regimen using metronomic prednisone, etoposide, and cyclophosphamide in the treatment of patients with relapsed or refractory NHL, in comparison with conventional salvage chemotherapy.
机译:目的迫切需要更好的治疗复发或难治性非霍奇金淋巴瘤(NHL)的策略。本研究旨在评估与常规抢救性化疗相比,使用节律性泼尼松,依托泊苷和环磷酰胺治疗复发性或难治性NHL患者的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号